Cobo-Ibañez, TatianaUrruticoechea-Arana, AnaRua-Figueroa, IñigoMartin-Martinez, Maria AOvalles-Bonilla, Juan GabrielGalindo, MariaCalvo-Alen, JaimeOlive, AlejandroFernandez-Nebro, AntonioMenor-Almagro, RaulTomero, EvaHorcada, LoretoUriarte-Itzazelaia, EstherMartinez-Taboada, Victor MAndreu, Jose LuisBoteanu, AlinaNarvaez, JavierBohorquez, CristinaMontilla, CarlosSantos, GregorioHernandez-Cruz, BlancaVela, PalomaSalgado, EvaFreire, MercedesHernandez-Beriain, Jose AngelDiez-Alvarez, ElviraExposito, LorenaFernandez-Berrizbeitia, OlaiaVelloso-Feijoo, Maria LuisaIbañez-Barcelo, MonicaLozano-Rivas, NuriaBonilla, GemaMoreno, MireiaRaya, EnriqueQuevedo-Vila, Victor EliseoVazquez-Rodriguez, Tomas RamonIbañez-Ruan, JesusMuñoz-Fernandez, SantiagoSanchez-Alonso, FernandoPego-Reigosa, Jose Maria2023-01-252023-01-252020-01-29Cobo-Ibáñez T, Urruticoechea-Arana A, Rúa-Figueroa I, Martín-Martínez MA, Ovalles-Bonilla JG, Galindo M, et al. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020 Feb;72(2):216-224http://hdl.handle.net/10668/14514To estimate the incidence and analyze any cancer-associated factors in patients with systemic lupus erythematosus (SLE), differentiating between hormone-sensitive (HS) and non-HS cancers. This was a retrospective multicenter study of a patient cohort from the Systemic Lupus Erythematosus Registry of the Spanish Society of Rheumatology. Included were the first cancer post-SLE diagnosis, clinical and sociodemographic information, cumulative damage, severity, comorbidities, treatments, and refractoriness. Cancers were classified as HS (prostate, breast, endometrium, and ovarian) and non-HS (the remainder). The standardized incidence ratio (SIR) was calculated and logistic regression models were built. A total of 3,539 patients (90.4% women) were included, 154 of whom had cancer (91% female), and 44 had HS cancer (100% female). The cancer SIR was 1.37 (95% confidence interval [95% CI] 1.15-1.59), with higher values in women age Cancer incidence in patients with SLE was higher than in the Spanish population, particularly among young women. This increase might be due to non-HS cancers, which would be associated with SLE involving greater cumulative damage where more ACE inhibitors are prescribed.enÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de CádizÁrea de Gestión Sanitaria Sur de SevillaNeoplasmsLupus Erythematosus, SystemicRheumatologyHormonesAdultAgedCohort StudiesFemaleHormonesHumansLongitudinal StudiesLupus Erythematosus, SystemicMaleMiddle AgedNeoplasmsRetrospective StudiesSpainYoung Adultresearch article31529686Restricted AccessLupus Eritematoso SistémicoDiagnóstico ClínicoHormonasReumatologíaInhibidores de la Enzima Convertidora de AngiotensinaPróstata10.1002/acr.240682151-4658https://repositorio.unican.es/xmlui/bitstream/10902/18466/1/HormonalDependenceCancer.pdf